Using the Common Sense Model of Self-Regulation to Review the Effects of Self-Monitoring of Blood Glucose on Glycemic Control for Non–Insulin-Treated Adults With Type 2 Diabetes

2013 ◽  
Vol 39 (4) ◽  
pp. 541-559 ◽  
Author(s):  
Jessica Y. Breland ◽  
Lisa M. McAndrew ◽  
Edith Burns ◽  
Elaine A. Leventhal ◽  
Howard Leventhal
2021 ◽  
Vol 104 (1) ◽  
pp. 171-178
Author(s):  
Estelle Fall ◽  
Nadia Chakroun-Baggioni ◽  
Philip Böhme ◽  
Salwan Maqdasy ◽  
Marie Izaute ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Jessica Y. Breland ◽  
Ashley M. Fox ◽  
Carol R. Horowitz ◽  
Howard Leventhal

The obesity epidemic is a threat to the health of millions and to the economic viability of healthcare systems, governments, businesses, and nations. A range of answers come to mind if and when we ask, “What can we, health professionals (physicians, nurses, nutritionists, behavioral psychologists), do about this epidemic?” In this paper, we describe the Common-Sense Model of Self-Regulation as a framework for organizing existent tools and creating new tools to improve control of the obesity epidemic. Further, we explain how the Common-Sense Model can augment existing behavior-change models, with particular attention to the strength of the Common-Sense Model in addressing assessment and weight maintenance beyond initial weight loss.


2014 ◽  
Vol 21 (6) ◽  
pp. 989-994 ◽  
Author(s):  
Lisa M. McAndrew ◽  
Pablo A. Mora ◽  
Karen S. Quigley ◽  
Elaine A. Leventhal ◽  
Howard Leventhal

2020 ◽  
Vol 32 (2) ◽  
pp. 51-60
Author(s):  
Minja Cho ◽  
Changkwan Lee ◽  
Eunjeong Lee ◽  
Miyoung Kim

2020 ◽  
Vol 8 (1) ◽  
pp. e001115 ◽  
Author(s):  
Eri Wada ◽  
Takeshi Onoue ◽  
Tomoko Kobayashi ◽  
Tomoko Handa ◽  
Ayaka Hayase ◽  
...  

IntroductionThe present study aimed to evaluate the effects of flash glucose monitoring (FGM) and conventional self-monitoring of blood glucose (SMBG) on glycemic control in patients with non-insulin-treated type 2 diabetes.Research design and methodsIn this 24-week, multicenter, open-label, randomized (1:1), parallel-group study, patients with non-insulin-treated type 2 diabetes at five hospitals in Japan were randomly assigned to the FGM (n=49) or SMBG (n=51) groups and were provided each device for 12 weeks. The primary outcome was change in glycated hemoglobin (HbA1c) level, and was compared using analysis of covariance model that included baseline values and group as covariates.ResultsForty-eight participants in the FGM group and 45 in the SMBG group completed the study. The mean HbA1c levels were 7.83% (62.1 mmol/mol) in the FGM group and 7.84% (62.2 mmol/mol) in the SMBG group at baseline, and the values were reduced in both FGM (−0.43% (−4.7 mmol/mol), p<0.001) and SMBG groups (−0.30% (−3.3 mmol/mol), p=0.001) at 12 weeks. On the other hand, HbA1c was significantly decreased from baseline values in the FGM group, but not in the SMBG group at 24 weeks (FGM: −0.46% (−5.0 mmol/mol), p<0.001; SMBG: −0.17% (−1.8 mmol/mol), p=0.124); a significant between-group difference was also observed (difference −0.29% (−3.2 mmol/mol), p=0.022). Diabetes Treatment Satisfaction Questionnaire score was significantly improved, and the mean glucose levels, SD of glucose, mean amplitude of glycemic excursions and time in hyperglycemia were significantly decreased in the FGM group compared with the SMBG group.ConclusionsGlycemic control was better with FGM than with SMBG after cessation of glucose monitoring in patients with non-insulin-treated type 2 diabetes.Trial registration numberUMIN000026452, jRCTs041180082.


Sign in / Sign up

Export Citation Format

Share Document